81 results about "Myelocytic leukemia" patented technology

The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.

The present invention provides a method of screening substances having property of causing apoptosis, and relates to a method of screening substances having property of causing apoptosis characterized by using cells which are expressing IAP (Integrin Associated Protein), and the relates to above screening method, wherein the cells used are myeloid cells, and relates to pharmaceutical compositions containing as the active ingredient the substances obtained by the above method, and the present invention makes it possible to differentiate, identify and screen readily and highly efficiently the substances, such as antibodies and the like, that have property of causing apoptosis on myeloid cells by using cells which are expressing IAP while using specific binding reactions of the substances, and the above specific substances thus obtained can be used by virtue of their characteristics as the active ingredient of pharmaceutical compositions such as anticancer agents and medicines for myelocytic leukemia and the like.

The invention discloses an AML (Acute Myelocytic Leukemia) cell segmentation method based on Meanshift cluster and morphological operations. The algorithm is to cluster a bone marrow cell and a cell nucleus from two aspects of spatial distance and color distance, and is combined with a series of morphological operations and the modified watershed conversion technology, so as to solve the accurate segmentation problem of the adherent bone marrow cell and bone marrow cell nucleus. The algorithm is high in stability, and good in robustness for segmenting the adherent bone marrow cells with different AML types under different illumination conditions.

The invention relates to a combined reagent for detecting acute myelocytic leukemia cells and a system thereof, wherein the combined reagent and the system thereof belong to the field of medical technology. The combined reagent comprises at least one selected from the following antibody combinations: a first antibody combination which comprises CD38, CD13, CD34, CD117, CD33, CD19, HLA-DR and CD45antibodies; a second antibody combination which comprises CD38, CD64, CD34, CD123, CD56, CD14, HLA-DR and CD45 antibodies; and a third antibody combination which comprises CD38, CD7, CD34, CD5, CD11b,CD15 and CD45 antibodies. The antibody combinations of the invention cover the expression marks of three systems of granulocyte, single cell and lymphocyte. A normal antibody expression mode is established. Tumor cells can be identified maximally. Furthermore, through a large number of experiment data, the antibodies in each combination have no problem of mutual expression inhibition. FurthermoreAML-MRD can be comprehensively and quickly detected with high sensitivity through multi-parameter flow type cell analysis.

The invention relates to a BCR/ABL fusion gene (P210bcr/abl) mRNA fluorescence quantitative PCR measurement detection reagent box which comprises lymphocyte segregating liquid, RNA extracting liquid A, RNA extracting liquid B, Oligo (dT) 12-18, RT reaction fluid, reverse transcriptase, quantitative PCR reaction fluid, standard sample, comparison sample, and DEPC water; wherein, a marked primer and a non-marked primer are contained in the quantitative PCR reaction fluid. The reagent box can accurately detect the BCR/ABL fusion gene (P210) mRNA level in the specimen to be detected by extracting the total RNA of medulla ossium or peripheral blood, obtaining cDNA through reverse transcriptase and being combined with a real-time fluorescence quantitative PCR measurement detection technology. The reagent box adopts the latest self-quenched probe technology, thereby having the advantages that the repetitiveness is good, the sensitivity is high, the cost is low, and the invention can be applied to the dynamic monitoring of chronic myelocytic leukemia diagnosis, curative effect observation, prognosis and micro residual leukemia (MRD).

The invention discloses 5-phenylpyridine-2-amine Bcr-Abl inhibitors as well as a preparation method and application thereof. A structural formula of the inhibitors is shown in the specification, wherein in the structural formula, R1 is acetyl, methylsulfonyl or pivaloyl; R2 is a mono-substituent or a di-substituent, and the substituent is alkoxy or halogen. The series of inhibitors have a certain inhibiting effect on ABL1 kinase in vitro, can inhibit proliferation of a tumor cell K562 and can be used for preparing antitumor drugs, especially CML (chronic myelocytic leukemia) drugs. The preparation method of the 5-phenylpyridine-2-amine Bcr-Abl inhibitors, which is provided by the invention, has the advantages of easiness in obtainment of raw materials, mild reaction conditions, simplicity in operation of reaction processes and cheap used reagents.

An objective of the present invention is to provide an activated Rho protein target protein derived from a human and a gene coding for the same. The present invention provides a protein derived from a human and a derivative thereof which has the following characteristics: (1) having activated Rho protein binding activity, (2) having profilin binding activity, (3) the gene coding for the protein being located at q31.2 of chromosome 5, and (4) having a molecular weight of about 150 kDa as measured by SDS-PAGE. Respiratory tract hypersensitivity, bronchial asthma, acute myelocytic leukemia (AML) and myelodysplasia syndrome (MDS) can be diagnosed using the nucleotide sequence coding for this protein.

The invention discloses a fluorescent reverse transcription-polymerase chain reaction (RT-PCR) kit for quantitatively detecting a leukemia translocation ETS leukemia acute myelocytic leukemia (TEL-AML)1 fusion gene and belongs to the field of in-vitro nucleic acid diagnosis. The kit comprises a quantitative reference substance, a negative reference substance, a positive reference substance, RT-PCR enzyme, PCREnhancer, diethypyrocarbonate (DEPC) water, fluorescent PCR reaction liquid I, fluorescent PCR reaction liquid II and ribose nucleic acid (RNA) extraction liquid. The kit comprises an RT-PCR system in which a fluorescent PCR technology is taken as basis, and forward and reverse primers and a fluorescent probe aiming at AMLI and TEL-AML1, can detect the RNA of AMLI and TEL-AML1 simultaneously under the same PCR condition, detect whether TEL-AML1 gene fusion occurs in a clinical sample conveniently and quickly, and provides important basis for leukemia diagnosis, typing, clinical treatment and prognosis diagnosis, and a new train of thought for clinical treatment.

Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating CML is provided, which avoids the toxic side-effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating acute myelocytic leukemia (AML) when co-administered with inducing agents which induce expression of antigens minimally displayed on the surface of myeloblasts.

The present invention provides a BCR-ABL fusion gene amplification kit and a BCR-ABL fusion gene detection kit, wherein the amplification kit has advantages of convenient use, rapid operation, and high sensitivity. According to the present invention, the BCR-ABL fusion gene can be subjected to typing and quantitation with the detection kit, such that the pathogenetic condition development and the prognosis of the chronic myelocytic leukemia patient can be monitored according to the BCR-ABL fusion gene detection result.

The present invention is directed to a nanoparticulate compositions of imatinib mesylate, or a salt or derivative thereof, having improved pharmacokinetic profiles and reduced fed/fasted variability. The nanoparticulate imatinib mesylate particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors and related diseases.

The invention relates to a kit for detecting an expression index of mRNA (messager Ribose Nucleic Acid) of a WT1 (Wilms Tumor 1) gene, and belongs to the field of biotechnology. The kit comprises detection primers, a fluorescent probe, a cDNA (complementary Deoxyribose Nucleic Acid) first strand synthesis reagent, a fluorescent quantitative PCR (Polymerase Chain Reaction) mixed solution, negative reference and positive reference, wherein the detection primers and the fluorescent probe comprise a WT1 gene primer, an internal reference gene ABL primer and a Taqman fluorescent probe. The WT1 gene is related with hematopoietic tumor incidence, is of over-expression in about 80% of patients with newly diagnosed acute myelocytic leukemia and acute lymphocytic leukemia, is recognized as a leukemia marker gene, and can serve as an independent minimal residue disease monitoring and prognosis prompting index. The level of the mRNA of the WT1 gene is detected by adopting a fluorescent quantitative PCR technology with higher sensitivity and specificity, and both the specificity and the sensitivity of a detection result are remarkably improved. The kit provides a brand-new quick, simple and convenient gene diagnosis technology for prognosing the acute myelocytic leukemia and the acute lymphocytic leukemia and confirming chemotherapy regimens.

The invention provides a kit for the prognostic stratification of AML (Acute Myelocytic Leukemia), which is capable of quickly detecting multigene/multisite mutation. By using the kit, a mutant site can be completely detected; further, the detection sensitivity is high; the entire experimental process from the preparation of a sample to the issue of a report can be completed within one day; the detection is quick and the detection result is accurate; the coverage degree is high; meanwhile, the quick guidance can be effectively provided for the prognostic analysis of the AML.

The invention discloses a peripheral blood TCR marker of acute myeloid leukemia and a detection kit and application of the peripheral blood TCR marker. The marker comprises at least one of proteins of which the sequences are as shown in SEQ ID NO.1-100. On the basis of a high-throughput sequencing method, only a small amount of peripheral blood needs to be adopted, RNA is extracted, an immune map library is established by treating a sample, then through high-throughput sequencing and TCR data analysis, firstly, a characteristic TCR sequence in the peripheral blood of acute myeloid leukemia is determined, then a test result of a to-be-tested sample is compared with the characteristic TCR sequence. Therefore, whether the patient suffers from acute myeloid leukemia is determined. According to the kit, a huge number of acute myeloid leukemia specific TCR sequences can be compared at the same time, and compared with single detection of one or more markers, the kit has higher specificity and accuracy, and the diagnosis efficiency is improved.

The invention relates to a novel use of Chinese herbal medicine monomer embelin, in particular to an application of the embelin in a preparation of a drug for inhibiting angiogenesis. The embelin is applied in the inhibition of angiogenesis dependent disease such as mammary cancer, colon cancer, lymphoma, acute myelocytic leukemia, rheumatoidarthritis, psoriasis, diabetic syndrome, hemangioma, etc. Experiments show that the embelin has remarkable inhibitory action in proliferation experiment, migration experiment, invasion experiment, cell tabulation experiment, the angiogenesis of chick embryo allantois, etc. in the human microvascular endothelial cells (HMEC-1), thereby being used for preparing the drug for inhibiting the angiogenesis.

This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R^1a, R^1b, R^2b, R^3a, R^3b, R⁴, R⁵, R⁶, R⁷, A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.

The invention discloses an assay kit for testing the relative expression of core-binding factor (CBF) beta/myosin 11 fusion genes, and the kit comprises red blood cell lysis buffer, TRIzol, chloroform, absolute ethyl alcohol, ReverTraAceqPCRRTKit, testing system polymerase chain reaction (PCR) reaction solution, positive control substance and negative control substance, and is characterized in that the testing system PCR reaction solution comprises THUNDERBIRDqPCRMIX, primers of CBF beta/MYH11-F, CBF beta/MYH11-A-R, CBF beta/MYH11-D-R and CBF beta/MYH11-E-R for amplifying a target gene, probe of CBF beta/MYH11-Prob, primers of abl-F and abl-R for amplifying an internal control gene, and probe of abl-Probe. The assay kit can be used for testing the expression level of the CBF beta/myosin 11 fusion genes of a patient suffering from human acute myelognous leukemia (AML), so the test time can be effectively saved, and the test precision is improved.

The invention discloses a kit capable of detecting expression quantity of BAALC (brain and acute leukemia cytoplasmic) gene mRNA (Messenger Ribose Nucleic Acid), belonging to the field of biotechnology. The kit comprises a detection primer and fluorescence probe, a cDNA first strand synthesis reagent, fluorogenic quantitative PCR (Polymerase Chain Reaction) mixed liquor, negative control and positive control, wherein the primers and fluorescence probes for detection include a BAALC gene primer, a reference gene ABL primer and a Taqman fluorescence probe. The BAALC gene is a sign of progenitor cell of early hematopoietic cell, and is abnormally expressed in acute and chronic patients with AML (Acute Myelocytic Leukemia), ALL (Acute Lymphocytic Leukemia) and CML (Chronic Myeloid Leukemia). According to the embodiment of the invention, the mRNA level of the BAALC gene is detected by fluorogenic quantitative PCR with high sensitivity and specificity, and the specificity and sensitivity of the detection result are both obviously improved. The kit can provide a brandnew, fast, simple and convenient gene diagnosis technology for clinically evaluating the diagnosis, prognosis and reappearance period of acute lymphocytic leukemia.

The invention discloses N,6 diphenylpyrimidine-4-amine Bcr-Abl inhibitors as well as a preparation method and application thereof. A structural formula of the inhibitors is shown in the specification, wherein in the structural formula, R is a mono-substituent or a di-substituent, and the substituent is alkyl, halogen or tertiary amino. The series of inhibitors have a certain inhibiting effect on ABL1 kinase in vitro, can inhibit tumor cell proliferation and can be used for preparing antitumor drugs, especially CML (chronic myelocytic leukemia) drugs. The preparation method of the N,6 diphenylpyrimidine-4-amine Bcr-Abl inhibitors, which is provided by the invention, has the advantages of easiness in obtainment of raw materials, mild reaction conditions, simplicity in operation of reaction processes and cheap used reagents.

The invention discloses 6-phenylpyridine-2-amine Bcr-Abl inhibitors as well as a preparation method and application thereof. A structural formula of the inhibitors is shown in the specification, wherein in the structural formula, R1 is acetyl, methylsulfonyl or pivaloyl; R2 is a mono-substituent or a di-substituent, and the substituent is alkyl or halogen. The series of inhibitors have a certain inhibiting effect on ABL1 kinase in vitro, can inhibit proliferation of a tumor cell K562 and can be used for preparing antitumor drugs, especially CML (chronic myelocytic leukemia) drugs. The preparation method of the 6-phenylpyridine-2-amine Bcr-Abl inhibitors, which is provided by the invention, has the advantages of easiness in obtainment of raw materials, mild reaction conditions, simplicity in operation of reaction processes and cheap used reagents.

The use of eriocalyxin B in the manufacture of medicaments for treating leukemia, wherein the leukemia include leukemia containing AML1-ETO fusion protein, acute promyelocytic leukemia, acute myelocytic leukemia and lymphocytic leukemia. Eriocalyxin B increases the level of peroxidate and influences the phosphorylation and degradation of IκBα to prevent NF-κB from getting into the nucleus in order to inhibition NF-κB pathway. Eriocalyxin B can decrease the phosphorylation of ERI1/2 and inhibit MAPK pathway. Eriocalyxin B can extend the life span of mice and decrease tumor volume in mice model of C57 leukemia and tumor transplantation.